Boston scientific receives fda clearance for lithovue™ elite single-use digital flexible ureteroscope system

New technology designed to help inform real-time clinical decisions during kidney stone procedures marlborough, mass. , feb. 3, 2023 /prnewswire/ -- boston scientific corporation (nyse: bsx) today announced u.s. food and drug administration (fda) 510(k) clearance of the lithovue™ elite single-use digital flexible ureteroscope system, the first ureteroscope system with the ability to monitor intrarenal pressure in real-time during ureteroscopy procedures.
BSX Ratings Summary
BSX Quant Ranking